In obesity, NNMT activity is unusually high in fat cells, which means a lot of nicotinamide gets thrown out before it can be turned into NAD+
The Economic Engine: Core Drivers of Telehealth Adoption This explosive market growth is not a bubble
REDEFINE 11: a higher-dose follow-up Novo Nordisk has a higher-dose CagriSema trial (REDEFINE 11) running in parallel, expected to report in the first half of 2027
A randomized clinical trial mixed 26 weeks of exenatide treatment for AUD with cognitive-behavioral therapy and showed optimistic results related to alcohol abstinence
Successfully weaning off tirzepatide without gaining weight requires strategic planning, including potential dose tapering under medical supervision, intensified lifestyle modifications, and realistic expectations about the biological challenges of weight maintenance
If your telehealth practice or pharmacy has been involved in compounding semaglutide or other GLP-1 drugs and youre unsure how these changes will impact your operations, Nixon Law Group is here to help